| 词条 | Conatumumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 460106777 | image = | type = mab | mab_type = mab | source = u | target = TRAIL-R2 (CD262) | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 896731-82-1 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 1P48L61KM0 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D09329 | C=6466 | H=10006 | N=1730 | O=2024 | S=40 | molecular_weight = 145.65 kg/mol | synonyms = anti-TRAIL receptor 2 monoclonal antibody, AMG-655 }}Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[1][2] The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011. References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association. {{Monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^National Cancer Institute: Definition of conatumomab 2 : Amgen|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。